{"transactions":[{"id":761497,"issuer":{"id":5242,"kind":"organization","name":"Verastem, Inc.","symbol":"VSTM"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T21:45:40.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"36,000 restricted stock units granted to the Reporting Person as an annual grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan (\"Annual Grant RSUs\"). Each Annual Grant RSU represents the contingent right to receive one share of Common Stock. The Annual Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"72,000 restricted stock units granted to the Reporting Person as an initial grant under the Issuer's Amended and Restated 2021 Equity Incentive Plan (\"Initial Grant RSUs\"). Each Initial Grant RSU represents the contingent right to receive one share of Common Stock. The Initial Grant RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) on each quarterly anniversary of May 21, 2026 (the \"Start Date\") until the award is fully vested on the date that is three (3) years from the Start Date, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date."}],"balance_after":108000,"source":{"system":"sec-edgar","filing":"0001104659-26-067048","document":"tm2615478-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1255856/000110465926067048/tm2615478-6_4seq1.xml","form_type":"4"}},{"id":2050661,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":625192,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.67,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":625192},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050660,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":275100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":9.12,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":275100},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050659,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":35302,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":35302},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050658,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":93500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":6.2,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":93500},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050657,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":16750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":15.7,"expiration_date":"2024-06-19","underlying":"Common Stock","underlying_shares":16750},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050656,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":99999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":30.8,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":99999},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050655,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":75366,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":6,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":75366},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050654,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":46000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":10.8,"expiration_date":"2026-01-07","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050653,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":8.4,"expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050652,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":7499,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":17.7,"expiration_date":"2024-01-29","underlying":"Common Stock","underlying_shares":7499},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050651,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":11999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":25.1,"expiration_date":"2023-06-26","underlying":"Common Stock","underlying_shares":11999},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050650,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":3249,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":77.2,"expiration_date":"2023-01-24","underlying":"Common Stock","underlying_shares":3249},"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2050649,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-01-19T17:11:51.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":333167,"price":15,"value":4997505.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-002183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002183/doc4.xml","form_type":"4"}},{"id":2077554,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":false,"shares":164525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company."}],"balance_after":625192,"derivative":{"exercise_price":3.67,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":164525},"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2077553,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":false,"shares":85722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":35302,"derivative":{"exercise_price":5.6,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":85722},"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2077552,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":false,"shares":26499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company."}],"balance_after":93500,"derivative":{"exercise_price":6.2,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":26499},"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2077551,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":true,"shares":164525,"price":3.67,"value":603806.75,"ownership":{"direct":true},"balance_after":340167,"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2077550,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":true,"shares":85722,"price":5.6,"value":480043.2,"ownership":{"direct":true},"balance_after":175642,"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2077549,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-22T16:46:26.000Z","date":"2022-12-20","kind":"exercise","acquired":true,"shares":26499,"price":6.2,"value":164293.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended."}],"balance_after":82920,"source":{"system":"sec-edgar","filing":"0001628280-22-032490","document":"wf-form4_167174557174898.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022032490/wf-form4_167174557174898.xml","form_type":"4"}},{"id":2388117,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-17T16:58:40.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":789717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company."}],"balance_after":789717,"derivative":{"exercise_price":3.67,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":789717},"source":{"system":"sec-edgar","filing":"0001628280-22-003055","document":"wf-form4_164513508741973.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022003055/wf-form4_164513508741973.xml","form_type":"4"}},{"id":2578951,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-09-03T17:12:01.000Z","date":"2021-09-01","kind":"purchase","acquired":true,"shares":15000,"price":6.48,"value":97200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.49, inclusive. The reporting person undertakes to provide to AVEO, any security holder of AVEO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,426 shares acquired under AVEO's 2010 Employee Stock Purchase Plan."}],"balance_after":49311,"source":{"system":"sec-edgar","filing":"0000899243-21-035140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924321035140/doc4.xml","form_type":"4"}},{"id":2746817,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T16:05:32.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 5, 2021 through February 5, 2025, subject to the Reporting Person's continued service to the Company."}],"balance_after":275000,"derivative":{"exercise_price":9.12,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000899243-21-016106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924321016106/doc4.xml","form_type":"4"}},{"id":3284340,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-07T17:43:04.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":1210250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company."}],"balance_after":1210250,"derivative":{"exercise_price":0.56,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":1210250},"source":{"system":"sec-edgar","filing":"0000899243-20-003702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924320003702/doc4.xml","form_type":"4"}},{"id":3359862,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-25T16:30:39.000Z","date":"2019-11-21","kind":"purchase","acquired":true,"shares":150000,"price":0.5973,"value":89595.0,"ownership":{"direct":true},"balance_after":318848,"source":{"system":"sec-edgar","filing":"0000899243-19-028068","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924319028068/doc4.xml","form_type":"4"}},{"id":3667896,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T16:30:52.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company."}],"balance_after":1200000,"derivative":{"exercise_price":0.62,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000899243-19-003033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924319003033/doc4.xml","form_type":"4"}},{"id":4078964,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-02T20:10:37.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 1, 2018, through February 1, 2022, subject to the Reporting Person's continued service to the Company."}],"balance_after":1000000,"derivative":{"exercise_price":3.08,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-002757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924318002757/doc4.xml","form_type":"4"}},{"id":4270998,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-28T17:10:50.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":188666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On Febuary 8, 2017, the reporting person was granted an option to purchase 283,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On Febuary 8, 2017, the reporting person was granted an option to purchase 283,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company."}],"balance_after":188666,"derivative":{"exercise_price":0.6,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":188666},"source":{"system":"sec-edgar","filing":"0000899243-17-017408","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924317017408/doc4.xml","form_type":"4"}},{"id":4368066,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-03-30T21:27:44.000Z","date":"2017-03-28","kind":"other","acquired":true,"shares":100000,"price":0.5,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of AVEO Pharmaceuticals, Inc."}],"balance_after":168848,"source":{"system":"sec-edgar","filing":"0000899243-17-008971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924317008971/doc4.xml","form_type":"4"}},{"id":4457094,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":43780,"kind":"person","name":"BAILEY MICHAEL P","position":1,"cik":"0001255856","reported_name":"BAILEY MICHAEL P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-10T16:22:43.000Z","date":"2017-02-08","kind":"grant","acquired":true,"shares":565000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in equal monthly installments from February 8, 2017, through February 8, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":565000,"derivative":{"exercise_price":0.6,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":565000},"source":{"system":"sec-edgar","filing":"0000899243-17-003468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924317003468/doc4.xml","form_type":"4"}}]}